7 Analysts Have This to Say About Day One Biopharmaceutical
Portfolio Pulse from Benzinga Insights
In the last quarter, Day One Biopharmaceutical (NASDAQ:DAWN) received 6 bullish and 1 somewhat bearish analyst ratings. The company's average 12-month price target is $39.29, down 6.45% from the previous average of $42.00.
May 18, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceutical received 6 bullish and 1 somewhat bearish analyst ratings in the last quarter, with an average 12-month price target of $39.29, down 6.45% from the previous average.
The majority of analyst ratings for Day One Biopharmaceutical are bullish, indicating a positive outlook for the stock. However, the decrease in the average 12-month price target suggests that analysts have slightly lowered their expectations for the stock's performance. This could lead to short-term upward pressure on the stock price, but with a lower potential upside than previously anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100